Ftse Mib
36.222,65
1,12%
DAX
20.864,88
1,12%
S&P 500
5.937,34
-0,21%
NASDAQ
19.338,29
-0,89%
Bitcoin
102.248,05
2,24%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Amylyx Pharmaceuticals Inc (AMLX) Amylyx Pharmaceuticals Inc (AMLX) Notizie

Amylyx Pharmaceuticals Inc

AMLX
3,50
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 11:19:23
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
10/1/202523:23EDGAR2Form 8-K - Current report
10/1/202523:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/1/202514:26BWAmylyx Pharmaceuticals Announces Pricing of Public Offering..
10/1/202512:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/1/202501:30BWAmylyx Pharmaceuticals Announces Proposed Public Offering of..
08/1/202523:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202523:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202515:00BWAmylyx Pharmaceuticals Appoints Dan Monahan as Chief..
30/12/202413:50EDGAR2Form 8-K - Current report
04/12/202413:30BWAmylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY..
27/11/202415:00BWAmylyx Pharmaceuticals to Present at the 7th Annual Evercore..
07/11/202414:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202413:07EDGAR2Form 8-K - Current report
07/11/202413:00BWAmylyx Pharmaceuticals Reports Third Quarter 2024 Financial..
07/11/202401:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/11/202415:00BWAmylyx Pharmaceuticals to Report Third Quarter 2024..
17/10/202415:12EDGAR2Form 8-K - Current report
17/10/202415:00BWAmylyx Pharmaceuticals Announces Positive Topline Results..
15/10/202415:00BWAmylyx Pharmaceuticals to Host Virtual Webcast to Discuss..
03/10/202421:06PRNUSKuehn Law Encourages Investors of Amylyx Pharmaceuticals,..
03/10/202400:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202400:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202400:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/9/202423:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/9/202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/9/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/8/202414:30BWAmylyx Pharmaceuticals to Participate in Upcoming Investor..
27/8/202400:49EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
12/8/202415:00BWAmylyx Pharmaceuticals Announces Publication of Data Showing..
08/8/202413:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202413:09EDGAR2Form 8-K - Current report
08/8/202413:00BWAmylyx Pharmaceuticals Reports Second Quarter 2024 Financial..
05/8/202415:00BWAmylyx Pharmaceuticals to Report Second Quarter 2024..
02/8/202415:00BWAmylyx Pharmaceuticals Receives Orphan Drug Designation From..
19/7/202401:00PRNUSKuehn Law Encourages Investors of Amylyx Pharmaceuticals,..
10/7/202413:09EDGAR2Form 8-K - Current report
10/7/202413:00BWAmylyx Pharmaceuticals Announces Acquisition of Phase..
09/7/202422:01BWAmylyx Pharmaceuticals to Host Conference Call to Discuss..
07/6/202422:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202422:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202422:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202422:07EDGAR2Form 8-K - Current report
04/6/202415:00BWAmylyx Pharmaceuticals to Present at the Goldman Sachs 45th..
17/5/202401:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202413:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202413:05EDGAR2Form 8-K - Current report
09/5/202413:00BWAmylyx Pharmaceuticals Reports First Quarter 2024 Financial..
08/5/202415:00BWAmylyx Pharmaceuticals to Present at the 2024 Bank of..
02/5/202415:00BWAmylyx Pharmaceuticals to Report First Quarter 2024..
10/4/202415:00BWAmylyx Pharmaceuticals Announces Interim Data From Ongoing..
Apertura: Min: Max:
Chiusura: 3,50

La tua Cronologia

NASDAQ
AMLX
Amylyx Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network